Kernal Biologics, Inc.
Kernal Biologics is a pioneering biotech company focused on developing advanced mRNA therapeutics using AI-driven targeted delivery and cell-specific translation. Their mission is to create precise, effective treatments for cancer, autoimmune diseases, and other serious illnesses, aiming to improve patient outcomes and challenge the standard of care.
Industries
Nr. of Employees
small (1-50)
Kernal Biologics, Inc.
Cambridge, Massachusetts, United States, North America
Products
In vivo CAR‑T mRNA‑LNP program (T‑cell targeted, hematological indications)
Systemic, T‑cell‑targeted mRNA‑LNP program that delivers CAR mRNA to T cells in vivo to enable in situ CAR‑T programming; demonstrated in vivo B‑cell depletion in preclinical studies.
Solid tumor‑targeted mRNA‑LNP program (tumor microenvironment selective translation)
mRNA‑LNP program designed for preferential translation within the tumor microenvironment, with reported high therapeutic index and tolerability in preclinical models.
Computational RNA design platform (transformer‑based LLM for mRNA prediction)
A machine learning platform including a transformer‑based large language model developed to predict mRNA stability and translation efficiency and to optimize sequences for stability, expression, and immunogenicity.
In vivo CAR‑T mRNA‑LNP program (T‑cell targeted, hematological indications)
Systemic, T‑cell‑targeted mRNA‑LNP program that delivers CAR mRNA to T cells in vivo to enable in situ CAR‑T programming; demonstrated in vivo B‑cell depletion in preclinical studies.
Solid tumor‑targeted mRNA‑LNP program (tumor microenvironment selective translation)
mRNA‑LNP program designed for preferential translation within the tumor microenvironment, with reported high therapeutic index and tolerability in preclinical models.
Computational RNA design platform (transformer‑based LLM for mRNA prediction)
A machine learning platform including a transformer‑based large language model developed to predict mRNA stability and translation efficiency and to optimize sequences for stability, expression, and immunogenicity.
Services
Licensing of non‑immunogenic mRNA designs and extra‑hepatic delivery
Out‑licensing of mRNA sequences engineered for low immunogenicity and targeted extra‑hepatic LNP delivery for non‑oncology therapeutic development.
Licensing of non‑immunogenic mRNA designs and extra‑hepatic delivery
Out‑licensing of mRNA sequences engineered for low immunogenicity and targeted extra‑hepatic LNP delivery for non‑oncology therapeutic development.
Expertise Areas
- mRNA therapeutics and sequence engineering
- Targeted lipid nanoparticle delivery
- In vivo cell programming and CAR‑T approaches
- Computational RNA design and machine learning
Key Technologies
- Lipid nanoparticle (LNP) targeted delivery
- Selective mRNA translation engineering
- Transformer‑based large language models for RNA
- Convolutional neural networks (CNN), LSTM, capsule networks